alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

118TH CONGRESS 

1ST SESSION H. R. 753 

To direct the Secretary of Veterans Affairs to use on-site regulated medical 

waste treatment systems at certain Department of Veterans Affairs facilities, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 2, 2023 

Mr. BOST introduced the following bill; which was referred to the Committee 

on Veterans’ Affairs 

A BILL 

To direct the Secretary of Veterans Affairs to use on-site 

regulated medical waste treatment systems at certain 

Department of Veterans Affairs facilities, and for other 

purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Department of Vet5 erans Affairs Creation of On-Site Treatment Systems Af6 fording Veterans Improvements and Numerous General 

7 Safety Enhancements Act’’ or the ‘‘VA COST SAVINGS 

8 Enhancements Act’’. 


pbinns on DSKJLVW7X2PROD with $$_JOB
2 

•HR 753 IH

1 SEC. 2. USE OF ON-SITE REGULATED MEDICAL WASTE 

2 TREATMENT SYSTEMS AT DEPARTMENT OF 

3 VETERANS AFFAIRS FACILITIES. 

4 (a) IDENTIFICATION OF FACILITIES.—The Secretary 

5 of Veterans Affairs shall identify Department of Veterans 

6 Affairs facilities that would benefit from cost savings asso7 ciated with the use of an on-site regulated medical waste 

8 treatment system over a five-year period. 

9 (b) REGULATED MEDICAL WASTE COST ANALYSIS

10 MODEL.—For purposes of carrying out subsection (a), the 

11 Secretary shall develop a uniform regulated medical waste 

12 cost analysis model to be used to determine the cost sav13 ings associated with the use of an on-site regulated med14 ical waste treatment system at Department facilities. Such 

15 model shall be designed to calculate savings based on— 

16 (1) the cost of treating regulated medical waste 

17 at an off-site location under a contract with a non18 Department entity; compared to 

19 (2) the cost of treating regulated medical waste 

20 on-site, based on the equipment specification of 

21 treatment system manufacturers, with capital costs 

22 amortized over a ten-year period. 

23 (c) INSTALLATION.—At each Department facility 

24 identified under subsection (a), the Secretary shall secure, 

25 install, and operate an on-site regulated medical waste 

26 treatment system. 


pbinns on DSKJLVW7X2PROD with $$_JOB
3 

•HR 753 IH

1 (d) REGULATED MEDICAL WASTE DEFINED.—In 

2 this section, the term ‘‘regulated medical waste’’ has the 

3 meaning given such term under section 173.134(a)(5) of 

4 title 49, Code of Federal Regulations, concerning regu5 lated medical waste and infectious substances, or any suc6 cessor regulation, except that, in the case of an applicable 

7 State law that is more expansive, the definition in the 

8 State law shall apply. 

9 SEC. 3. NO ADDITIONAL FUNDS AUTHORIZED. 

10 No additional funds are authorized to be appro11 priated to carry out the requirements of this Act. Such 

12 requirements shall be carried out using amounts otherwise 

13 authorized to be appropriated. 

Æ 


pbinns on DSKJLVW7X2PROD with $$_JOB
<TABLE> <S> <C>

<ARTICLE> 9
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                           7,090
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                    316,347
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                                 0
<LOANS>                                        369,514
<ALLOWANCE>                                      3,056
<TOTAL-ASSETS>                                 717,517
<DEPOSITS>                                     443,705
<SHORT-TERM>                                   206,681
<LIABILITIES-OTHER>                              6,632
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                      60,499
<TOTAL-LIABILITIES-AND-EQUITY>                 717,517
<INTEREST-LOAN>                                 27,016
<INTEREST-INVEST>                               17,501
<INTEREST-OTHER>                                   744
<INTEREST-TOTAL>                                45,261
<INTEREST-DEPOSIT>                              14,991
<INTEREST-EXPENSE>                              23,223
<INTEREST-INCOME-NET>                           22,038
<LOAN-LOSSES>                                      642
<SECURITIES-GAINS>                                   4
<EXPENSE-OTHER>                                 18,487
<INCOME-PRETAX>                                  5,761
<INCOME-PRE-EXTRAORDINARY>                       3,530
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,530
<EPS-PRIMARY>                                      .90
<EPS-DILUTED>                                      .86
<YIELD-ACTUAL>                                    3.46
<LOANS-NON>                                      2,193
<LOANS-PAST>                                       297
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                  3,080
<ALLOWANCE-OPEN>                                 2,833
<CHARGE-OFFS>                                      454
<RECOVERIES>                                        35
<ALLOWANCE-CLOSE>                                3,056
<ALLOWANCE-DOMESTIC>                             3,056
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
§ 556.3 Definitions. As used in this part: *Acceptable daily intake (ADI)* means the daily intake which, during up to an entire life of a human, appears to be without adverse effects or harm to the health of the consumer. The ADI most often will be set on the basis of the drug's toxicological, microbiological, or pharmacological properties. It is usually expressed in micrograms or milligrams of the chemical per kilogram of body weight per day.
*Acute reference dose (ARfD)* means an estimate of the amount of residues expressed on a body weight basis that can be ingested in a period of 24 hours or less without adverse effects or harm to the health of the human consumer.
*Edible tissues* means muscle, liver, kidney, fat, skin with fat in natural proportions, whole eggs, whole milk, and honey.
*Marker residue* means the residue whose concentration is in a known relationship to the concentration of total residue in an edible tissue.
*mg/kg* means milligrams per kilogram.
*Not required,* in reference to tolerances in this part, means that at the time of approval: ( 1 ) No withdrawal period was necessary for residues of the drug to deplete to or below the concentrations considered to be safe, or an adequate withdrawal period was inherent in the proposed drug use, and there was a rapid depletion of residues, so there was no concern about residues resulting from misuse or overdosing; or
( 2 ) No withdrawal period was necessary because the drug was poorly absorbed or metabolized rapidly so as to make selection of an analyte impractical or impossible.
*ppb* means parts per billion (equivalent to nanograms per gram (ng/g) or μg/kg).
*ppm* means parts per million (equivalent to micrograms per gram (μg/g) or mg/kg).
*ppt* means parts per trillion (equivalent to picograms per gram (pg/g) or nanograms per kilogram (ng/kg)).
*Residue* means any compound present in edible tissues that results from the use of a drug, and includes the drug, its metabolites, and any other substance formed in or on food because of the drug's use.
*Target tissue* means the edible tissue selected to monitor for residues in the target animals.
*Tolerance* means the maximum concentration of a marker residue, or other residue indicated for monitoring, that can legally remain in a specific edible tissue of a treated animal.
*Total residue* means the aggregate of all compounds that results from the use of an animal drug, including the drug, its metabolites, and any other substances formed in or on food because of such drug use.
*μg/kg* means microgram per kilogram.
*Zero,* in reference to tolerances in this part, means any residues detected in the edible tissue renders it unsafe.
<PAGE>
                                                                    Exhibit 10.1


                       CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the incorporation by reference in the Registration
Statements (Forms F-3 No. 333-12096, No. 333-13550 and No. 333-84510) of
Deutsche Telekom AG and in the related Prospectuses of our report dated
March 17, 2003, with respect to the consolidated financial statements of
Deutsche Telekom AG included in this Annual Report on Form 20-F for the year
ended December 31, 2002.


April 14, 2003



Ernst & Young
Deutsche Allgemeine Treuhand AG
Wirtschaftspruefungsgesellschaft
Stuttgart



(Prof. Dr. Pfitzer)                         (Hollweg)
Wirtschaftspruefer                          Wirtschaftspruefer


PwC Deutsche Revision
Aktiengesellschaft
Wirtschaftspruefungsgesellschaft
Frankfurt am Main



(Frings)                                    (Laue)
Wirtschaftspruefer                          Wirtschaftspruefer
\\DC - 065480/000002 - 6410804 v1 1

Hogan Lovells US LLP

Columbia Square

555 Thirteenth Street, NW

Washington, DC 20004

T +1 202 637 5600

F +1 202 637 5910

www.hoganlovells.com

February 6, 2015

Lauralyn Remo, Chief

Air Carrier Fitness Division

U.S. Department of Transportation

1200 New Jersey Avenue, SE

Washington, DC 20590

Re: Aerodynamics Incorporated -(Docket DOT-OST-2014-0114)

Dear Ms. Remo:

This letter clarifies and updates Michael L. Hoyle’s status with Aerodynamics Inc.

and its parent companies, ADI Holdings Company, Inc. and Aviation Capital Partners, LLC

(collectively, the “Companies”).

ADI’s Application for scheduled authority filed on June 25, 2014 listed Mr. Hoyle as

Chairman of the Boards of Directors of the Companies. See, Application, Attachments F

and K. Mr. Hoyle resigned his position in 2014. He does not hold any ownership,

management, employment, board, consulting or sales agency position with the

Companies. See, attached Declaration of Michael Hoyle.

__________________________________

Robert E. Cohn

Patrick R. Rizzi

HOGAN LOVELLS US LLP

Columbia Square

555 Thirteenth Street, NW

Washington, DC 20004

Telephone: (202) 637-4999/-5659

Counsel for

Cc: Catherine O’Toole AERODYNAMICS INCORPORATED
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM IDS MANAGED
FUTURES II, L.P. FOR THE FIRST QUARTER OF 2000 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH 10-Q.
</LEGEND>
<CIK> 0000813831
<NAME> IDS MANAGED FUTURES II, L.P.

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                       7,628,434
<SECURITIES>                                         0
<RECEIVABLES>                                   36,133
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             7,664,567
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               7,664,567
<CURRENT-LIABILITIES>                          265,040
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   7,399,526
<TOTAL-LIABILITY-AND-EQUITY>                 7,664,567
<SALES>                                              0
<TOTAL-REVENUES>                             (600,871)
<CGS>                                                0
<TOTAL-COSTS>                                  199,948
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                800,820
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            800,820
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   800,820
<EPS-BASIC>                                    (52.55)
<EPS-DILUTED>                                  (52.55)


</TABLE>
§ 520.2345g Tetracycline hydrochloride and sodium novobiocin tablets. ( a ) *Specifications.* Each tablet contains the equivalent of 60 milligrams of tetracycline hydrochloride and 60 milligrams of novobiocin, or 180 milligrams of tetracycline hydrochloride and 180 milligrams of novobiocin.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* 10 milligrams of each antibiotic per pound of body weight (one single-strength tablet for each 6 pounds or one triple-strength tablet for each 18 pounds).
( 2 ) *Indications for use.* Treatment of acute or chronic canine respiratory infections such as tonsillitis, bronchitis, and tracheobronchitis when caused by pathogens susceptible to tetracycline and/or novobiocin, such as *Staphylococcus* spp. and *Escherichia coli.*
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37329, Aug. 18, 1992, as amended at 79 FR 28831, May 20, 2014]
- 200YR01
- 200YR02
- 200YR03
- 200YR04
- 200YR05
- 200YR06
- 200YR07
- 200YR08
- 200YR09
- 200YR10
- 200YR11
- 200YR12
- 200YR13
- 200YR14
- 200YR15
- 200YR16
- 200YR17
- 200YR18
- 200YR19
- 200YR20

    -       - Superintendent of Documents
      - 2023-07-14T00:16:25-0400
      - Government Publishing Office, Washington, DC 20401
      - Government Publishing Office
      - Government Publishing Office attests that this document has not been altered since it was disseminated by Government Publishing Office
§ 582.6185 Calcium acetate. ( a ) *Product.* Calcium acetate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
#### Mitchell Carlton SIMS, Petitioner-Appellant, v. *1221Jill BROWN, Warden,* Respondent-Appellee.

No. 03-99007.

United States Court of Appeals, Ninth Circuit.

Argued and Submitted June 9, 2005.

Filed Sept. 21, 2005.

Amended Dec. 8, 2005.

Trevor W. Morrison and John H. Blume, Cornell Law School, Ithaca, NY, for the petitioner-appellant.

David F. Glassman, Deputy Attorney General, Los Angeles, CA, for the respondent-appellee.

Before B. FLETCHER, RYMER, and FISHER, Circuit Judges.

*

 Jill Brown is substituted for her predecessor, Jeanne Woodford, pursuant to Fed. R. App. P. 43(c)(2).

ORDER

The majority opinion filed September 21, 2005, is amended as follows:

Page 13519, line 6: delete sentence beginning with “Indeed, Sims submitted no evidence.... ”

With this amendment, the majority of the panel votes to deny the petition for rehearing. Judges Rymer and Fisher vote to deny the petition for rehearing en banc. Judge B. Fletcher would grant the panel rehearing and recommends en banc rehearing.

The full court has been advised of the petition for rehearing en banc, and no judge of the court has requested on whether to rehear the matter en banc. Fed. R.App. P. 35.

The petition for rehearing and petition for rehearing en banc are DENIED.
§ 582.3637 Potassium metabisulfite. ( a ) *Product.* Potassium metabisulfite.
( b ) [Reserved]
( c ) *Limitations, restrictions, or explanation.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice, except that it is not used in meats or in food recognized as source of vitamin B1.
oofr-/r

ELECTRONIC RECORD

COA# 11-12-00351-CR OFFENSE: 19.03

James Doyle Burwell v.

STYLE: The State of Texas COUNTY: Ector

AFFIRMED/REVERSED

COA DISPOSITION: & RENDERED TRIAL COURT: 70th District Court

DATE: 11/20/14 Publish: NO TC CASE #: A-39,270

IN THE COURT OF CRIMINAL APPEALS

James Doyle Burwell v.

style: The State of Texas

APPELLANT*** Petition

FOR DISCRETIONARY REVIEW IN CCA IS:

cca#: PD-0006-15

CCA Disposition:

DATE:

RfFobeTp JUDGE:

DATE: Od}l#/jU>tS SIGNED: PC:

JUDGE: TM UJAdJsC— PUBLISH: DNP:

MOTION FOR

REHEARING IN CCA IS:

JUDGE:

ELECTRONIC RECORD
Exhibit 31.2
 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
      (a)
    
    Designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being
prepared;(b)
    
    Designed such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;(c)
    
    Evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such
evaluation; and(d)
    
    Disclosed in this report any change in the registrants internal control over financial
reporting that occurred during the registrants most recent fiscal quarter (the
registrants fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrants internal control
over financial reporting; and
 
 (a)
    
    All significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably likely to adversely
affect the registrants ability to record, process, summarize and report financial
information; and
 16




---



##### 



(b)
    
    Any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrants internal control over financial
reporting.
 Dated: July 25, 2008
    By:
    /s/ Gerald Y. NgGerald Y. NgChief Financial Officer, Senior Vice President,
Secretary and Treasurer (Principal Financial
and
Accounting Officer) 17
October 31, 2013



### JUDGMENT 

## The Fourteenth Court of Appeals

NESTOR GOYTIA AS NEX T FRIEND FOR A.A.P

. , A CHILD , Appellant

NO. 14

- 13

- 00603

- CV V.

VERONICA PAREDES AND ANGEL PAREDES , Appellee s

________________________________ Today the Court heard appellant's motion to dismiss the appeal from the judgment signed by the court below on April 26, 2013. Having considered the motion and found it meritor ious, we order the appeal DISMISSED

. We further order that all costs incurred by reason of this appeal be paid by appellant, Nestor Goytia

. We further order that mandate be issued immediately. We further order this decision certified below for observance.
Editorial Note on Part 14
Editorial Note: Nomenclature changes to part 14 appear at 88 FR 45065, July 14, 2023.

§ 14.20 Notice of hearing before an advisory committee. ( a ) Before the first of each month, and at least 15 days in advance of a meeting, the Commissioner will publish a notice in the Federal Register of all advisory committee meetings to be held during the month. Any advisory committee meetings for that month called after the publication of the general monthly notice are to be announced in the Federal Register on an individual basis at least 15 days in advance. The Commissioner may authorize an exception to these notice requirements in an emergency or for other reasons requiring an immediate meeting of an advisory committee, in which case public notice will be given at the earliest time and in the most accessible form feasible including, whenever possible, publication in the Federal Register.
( b ) The Federal Register notice will include— ( 1 ) The name of the committee;
( 2 ) The date, time, and place of the meeting;
( 3 ) The general function of the committee;
( 4 ) A list of all agenda items, showing whether each will be discussed in an open or closed portion of the meeting;
( 5 ) If any portion of the meeting is closed, a statement of the time of the open and closed portions;
( 6 ) The nature of the subjects to be discussed during, and the reasons for closing, any closed portion of the meeting;
( 7 ) The time set aside for oral statements and other public participation;
( 8 ) The name, address, and telephone number of the advisory committee Designated Federal Officer and any other agency employee designated as responsible for the administrative support for the advisory committee;
( 9 ) A statement that written submissions may be made to the advisory committee through the Designated Federal Officer at any time, unless a cutoff date has been established under § 14.35(d)(2);
( 10 ) When a notice is published in the Federal Register less than 15 days before a meeting, an explanation for the lateness of the notice; and
( c ) If a public hearing before an advisory committee is used in lieu of a formal evidentiary public hearing under § 14.1(a)(3), an initial notice of hearing is to be published separately in the Federal Register containing all the information described in § 12.32(e). This procedure may be used for any other hearing before an advisory committee when the Commissioner concludes, as a matter of discretion, that it would be informative to the public.
( d ) A list of advisory committee meetings will be distributed to the press by the Associate Commissioner for Public Affairs.
[44 FR 22351, Apr. 13, 1979, as amended at 47 FR 26375, June 1, 1982; 54 FR 9035, Mar. 3, 1989; 66 FR 6469, Jan. 22, 2001; 66 FR 12850, Mar. 1, 2001]